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Neurolymphomatosis (NL) is a rare manifestation of
lymphoma [1]. CT and MRI have been used to detect
NL, to stage the extent of the nerve involvement and to
guide biopsy. Recent reports have demonstrated the value
of FDG-PET/CT in patients with NL [2–4]. Here we
present the FDG-PET/CT imaging follow-up of a 56-year-
old patient with diffuse large B-cell lymphoma initially
presenting as stage IE involving the urinary bladder and
presacral area. After six cycles of chemotherapy and pelvic
radiation therapy, a complete response was documented.
However, there was relapse of the lymphoma, restricted to
neural structures. In a–c the PET/CT images demonstrate
increased FDG uptake in the cranial nerves, delineated on
fused axial images [b, gasserian ganglion of the trigeminal
nerve (arrows) and c the cervical and lumbar nerve roots
(arrows)]. The patient was treated with high-dose metho-
trexate and subsequent radiation therapy. Six weeks after
the end of radiation therapy, progressive NL (d–f) in the
brachial (e, arrows) and lumbosacral plexus (f, arrows)
was observed.
Because in NL nerve biopsies may fail and MRI may not
be sufficiently sensitive to show the entire extent of nerve
involvement, FDG-PET/CT with whole-body imaging and
exact anatomical correlation is useful in staging, biopsy
guidance, treatment planning and therapy assessment [5].
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